Fig. 2
From: Carrier-free multifunctional nanomedicine for intraperitoneal disseminated ovarian cancer therapy
Therapeutic effect and mechanism of THZ1 and Alendronate in vitro. A GESA plot for genes of cell cycle after THZ1 treatment. B Flow cytometric analysis of SKOV3 cells treated with THZ1 for 24 h at different concentrations. C Quantitative cell cycle analysis of different phases in THZ1 treatment groups with different concentrations. D Cell viability of SKOV3 treated with THZ1 at different concentrations for 24 and 48 h. E Detection of apoptotic SKOV3 cells after treatment with THZ1 at concertrantion of 0, 0.25, 0.5 and 1 μM for 24 h by flow cytometry. F Scratch assay for cell migration. Scratch edges were recorded at 24 h after scratching and treating with alendronate at concentration of 75, 150 and 300 μM (yellow dotted boxes marked the scratch edges). G Quantification of the percentage of the wound area in scratch migration assay. H Cell viability of SKOV3 treated with different concentrations of NaALN for 24 and 48 h